Retrospective analysis of topotecan administered weekly in heavily pretreated recurrent epithelial ovarian carcinoma patients.

被引：0
|
作者：
O'Malley, D [1 ]
Makkenchery, A [1 ]
Tangir, J [1 ]
Kelly, M [1 ]
Azodi, M [1 ]
Chambers, S [1 ]
Schwartz, P [1 ]
Rutherford, T [1 ]
机构：
[1] Yale Univ, Med Ctr, New Haven, CT USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2004年 / 22卷 / 14期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
5079
引用
收藏
页码：468S / 468S
页数：1
相关论文
共 50 条
  • [31] Single agent trabectedin in heavily pretreated patients with recurrent ovarian cancer
    Adam, Jean-Philippe
    Boumedien, Feriel
    Letarte, Nathalie
    Provencher, Diane
    GYNECOLOGIC ONCOLOGY, 2017, 147 (01) : 47 - 53
  • [32] Bevacizumab plus cyclophosphamide in heavily pretreated patients with recurrent ovarian cancer
    Chura, Justin C.
    Van Iseghem, Kelin
    Downs, Levi S., Jr.
    Carson, Linda F.
    Judson, Patricia L.
    GYNECOLOGIC ONCOLOGY, 2007, 107 (02) : 326 - 330
  • [33] Pegylated liposomal doxorubicin in heavily pretreated epithelial ovarian cancer patients
    Gorumlu, G.
    Kucukzeybek, Y.
    Kemal-Gul, M.
    Karaca, B.
    Cosan-Terek, M.
    Karabulut, B.
    Sanli, U. A.
    Akman, L.
    Ozsaran, A.
    Dikmen, Y.
    Uslu, R.
    JOURNAL OF BUON, 2008, 13 (03): : 349 - 352
  • [34] Feasibility study of oral cyclophosphamide salvage therapy for the treatment of heavily pretreated patients with recurrent epithelial ovarian cancer
    Watanabe, Yoh
    Etoh, Tomomaro
    Koike, Eiji
    Mizuno, Yoshiaki
    Wang, Wei-Min
    Hoshiai, Hiroshi
    INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 2010, 15 (05) : 468 - 471
  • [35] Weekly topotecan as first-line treatment for recurrent or persistent epithelial ovarian cancer (EOC).
    Safra, T
    Menczer, J
    Inbar, M
    En-Shem, E
    Glezerman, M
    Grisaro, D
    Ron, I
    Levy, T
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 482S - 482S
  • [36] Feasibility study of oral cyclophosphamide salvage therapy for the treatment of heavily pretreated patients with recurrent epithelial ovarian cancer
    Yoh Watanabe
    Tomomaro Etoh
    Eiji Koike
    Yoshiaki Mizuno
    Wei-Min Wang
    Hiroshi Hoshiai
    International Journal of Clinical Oncology, 2010, 15 : 468 - 471
  • [37] Effect of weekly administration of bevacizumab, gemcitabine, and oxaliplatin in patients with heavily pretreated ovarian cancer
    Ikeda, Yuji
    Kikuchi, Yoshihiro
    Takano, Masashi
    Goto, Tomoko
    Kouta, Hiroko
    Sasaki, Naoki
    Kudoh, Kazuya
    Oda, Katsutoshi
    Nagasaka, Tsuneki
    Kita, Tsunekazu
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [38] A prospective randomized trial of thalidomide with topotecan compared with topotecan alone in women with recurrent epithelial ovarian carcinoma
    Downs, Levi S., Jr.
    Judson, Patricia L.
    Argenta, Peter A.
    Ghebre, Rahel
    Geller, Melissa A.
    Bliss, Robin L.
    Boente, Matthew P.
    Nahhas, William A.
    Abu-Ghazaleh, Samir Z.
    Chen, M. Dwight
    Carson, Linda F.
    CANCER, 2008, 112 (02) : 331 - 339
  • [39] A preliminary retrospective analysis of weekly topotecan in recurrent smallcell lung cancer.
    Kasturi, VK
    Eckardt, JR
    Greco, FA
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 705S - 705S
  • [40] Single agent trabectedin in heavily pretreated patients with recurrent ovarian cancer (ROC).
    Boumedien, Feriel
    Adam, Jean-Philippe
    Akkour, Khalid
    LeTarte, Nathalie
    Provencher, Diane M.
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
12345